AMS Reports 29% Revenue Growth, Raises Dividend by 10%

AMS Reports Strong Growth and Increased Dividend

UK-based medical device manufacturer AMS announced a preliminary 29% revenue growth for 2025, fueled by organic expansion and strategic acquisitions. Reflecting confidence in its outlook, the company's board proposed a 10% increase in the full-year dividend.

Financial Highlights and Key Drivers

The company's adjusted EBITDA saw a 24% increase, while adjusted diluted earnings per share rose by 12%. This growth was largely driven by the full-year contributions from the Peters Surgical and Syntacoll acquisitions, which expanded the product portfolio. The Surgical division delivered a particularly strong performance in the US and Asia-Pacific regions.

Future Outlook and Projections

For 2026, AMS projects revenue of £245.3 million and an adjusted EBITDA of £55.2 million. Continued strong growth is expected from the Surgical division, alongside modest growth in the restructured Woundcare business. The company also anticipates multiple new product approvals starting from 2026.

Summary

AMS's robust 2025 financial results, combined with a positive forecast for 2026, underscore a successful strategy of acquisition-led and organic growth that positions the company for future expansion.

FAQ

Q: What were the main drivers of AMS's 2025 revenue growth?
A: The 29% revenue growth was driven by a combination of organic business expansion and the successful integration of the Peters Surgical and Syntacoll acquisitions.

Q: What is AMS's dividend proposal for 2025?
A: The board has proposed a 10% increase in the full-year dividend, citing confidence in the company's performance and future outlook.

Source: Investing.com